Last reviewed · How we verify
Prostin (PGE2) tablets
Prostin (PGE2) is a prostaglandin E1 analog that binds to prostaglandin receptors to promote vasodilation, inhibit platelet aggregation, and improve blood flow.
Prostin (PGE2) is a prostaglandin E1 analog that binds to prostaglandin receptors to promote vasodilation, inhibit platelet aggregation, and improve blood flow. Used for Patent ductus arteriosus (PDA) in neonates, Peripheral vascular disease and intermittent claudication.
At a glance
| Generic name | Prostin (PGE2) tablets |
|---|---|
| Sponsor | Wolfson Medical Center |
| Drug class | Prostaglandin E1 analog |
| Target | Prostaglandin E receptors (EP1, EP2, EP3, EP4) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PGE2 (dinoprostone) acts as a prostanoid receptor agonist, primarily targeting EP receptors on vascular smooth muscle and platelets. This leads to increased cAMP levels, resulting in vasodilation, reduced platelet aggregation, and improved microcirculation. The drug is used to maintain ductal arteriosus patency in neonates and for other vascular indications.
Approved indications
- Patent ductus arteriosus (PDA) in neonates
- Peripheral vascular disease and intermittent claudication
Common side effects
- Apnea
- Fever
- Hypotension
- Diarrhea
- Flushing
Key clinical trials
- Mechanical Dilation of the Cervix in a Scarred Uterus (NA)
- What After the First Propess (PHASE2)
- Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy (NA)
- Propess Versus Prostin for Induction of Labour in Women With Term PROM (PHASE4)
- Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients (PHASE4)
- Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion (NA)
- Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women (NA)
- Vaginal Dinoprostone Administration Prior to Intrauterine Device Insertion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostin (PGE2) tablets CI brief — competitive landscape report
- Prostin (PGE2) tablets updates RSS · CI watch RSS
- Wolfson Medical Center portfolio CI